CSIR Central

Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses

Metadata of CSIR Papers

View Archive Info
 
 
Field Value
 
Title Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses
 
Creator Sharma, P
Ghoshal, N
 
Subject Chemistry, Multidisciplinary; Computer Science, Information Systems; Computer Science, Interdisciplinary Applications
 
Description C-Jun N-terminal kinase (JNK) is a therapeutic target for inhibitors which may provide clinical benefit in the pathogenesis of rheumatoid arthritis ( RA) as well as in various apoptosis-related disorders. The benzothiazol-2-yl acetonitrile derivatives, recently reported by Pascale et al. (J. Med. Chem. 2005, 48, 45964607), are the first generation JNK inhibitors of this class. To understand inhibitory mechanisms and elucidate pharmacophoric properties of these derivatives molecular docking and 3D-QSAR studies were performed on a set of 44 compounds. Ligand Fit module of Cerius2 (4.9) was employed to locate the binding orientations of all the compounds within the JNK-3 ATP binding site. A good correlation (r(2) = 0.810) between the calculated binding free energies (-PMF score) and the experimental inhibitory activities suggests that the identified binding conformations of these potential inhibitors are reliable. Based on the binding conformations, robust and highly predictive 3D-QSAR models were developed with conventional r(2) 0.886 and 0.802, full cross-validation r(2) 0.980 and 0.788, and predictive r(2) 0.965 and 0.968 for MFA and MSA, respectively. The interaction mode was demonstrated taking into consideration inhibitor conformation, hydrogen bonding, and electrostatic interaction. The 3D-QSAR model built in this study will provide clear guidelines for a novel inhibitor design based on the benzothiazole derivatives against JNK-3 for the treatment of inflammatory disorders.
 
Publisher AMER CHEMICAL SOCWASHINGTON1155 16TH ST, NW, WASHINGTON, DC 20036 USA
 
Date 2011-09-20T12:12:11Z
2011-09-20T12:12:11Z
2006
 
Type Article
 
Identifier JOURNAL OF CHEMICAL INFORMATION AND MODELING
1549-9596
http://hdl.handle.net/123456789/14160
 
Language English